Putting a price tag on novel autologous cellular therapies

Mohamed Abou-El-Enein, Gerhard Bauer, Nicholas Medcalf, Hans Dieter Volk, Petra Reinke

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Cell therapies, especially autologous therapies, pose significant challenges to researchers who wish to move from small, probably academic, methods of manufacture to full commercial scale. There is a dearth of reliable information about the costs of operation, and this makes it difficult to predict with confidence the investment needed to translate the innovations to the clinic, other than as small-scale, clinician-led prescriptions. Here, we provide an example of the results of a cost model that takes into account the fixed and variable costs of manufacture of one such therapy. We also highlight the different factors that influence the product final pricing strategy. Our findings illustrate the need for cooperative and collective action by the research community in pre-competitive research to generate the operational models that are much needed to increase confidence in process development for these advanced products.

Original languageEnglish (US)
JournalCytotherapy
DOIs
StateAccepted/In press - Mar 14 2016

Fingerprint

Costs and Cost Analysis
Health Services Research
Therapeutics
Cell- and Tissue-Based Therapy
Prescriptions
Research Personnel
Research

Keywords

  • Adoptive T-cell therapy
  • Commercialization
  • Cost of goods
  • Good manufacturing practice
  • Immunotherapy
  • Market adoption
  • Price
  • Regulation
  • Reimbursement
  • Scale-up

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Oncology
  • Genetics(clinical)
  • Transplantation
  • Cancer Research
  • Cell Biology

Cite this

Abou-El-Enein, M., Bauer, G., Medcalf, N., Volk, H. D., & Reinke, P. (Accepted/In press). Putting a price tag on novel autologous cellular therapies. Cytotherapy. https://doi.org/10.1016/j.jcyt.2016.05.005

Putting a price tag on novel autologous cellular therapies. / Abou-El-Enein, Mohamed; Bauer, Gerhard; Medcalf, Nicholas; Volk, Hans Dieter; Reinke, Petra.

In: Cytotherapy, 14.03.2016.

Research output: Contribution to journalArticle

Abou-El-Enein, Mohamed ; Bauer, Gerhard ; Medcalf, Nicholas ; Volk, Hans Dieter ; Reinke, Petra. / Putting a price tag on novel autologous cellular therapies. In: Cytotherapy. 2016.
@article{36c92f41ad0e4bc1b5e4aa681515b8b4,
title = "Putting a price tag on novel autologous cellular therapies",
abstract = "Cell therapies, especially autologous therapies, pose significant challenges to researchers who wish to move from small, probably academic, methods of manufacture to full commercial scale. There is a dearth of reliable information about the costs of operation, and this makes it difficult to predict with confidence the investment needed to translate the innovations to the clinic, other than as small-scale, clinician-led prescriptions. Here, we provide an example of the results of a cost model that takes into account the fixed and variable costs of manufacture of one such therapy. We also highlight the different factors that influence the product final pricing strategy. Our findings illustrate the need for cooperative and collective action by the research community in pre-competitive research to generate the operational models that are much needed to increase confidence in process development for these advanced products.",
keywords = "Adoptive T-cell therapy, Commercialization, Cost of goods, Good manufacturing practice, Immunotherapy, Market adoption, Price, Regulation, Reimbursement, Scale-up",
author = "Mohamed Abou-El-Enein and Gerhard Bauer and Nicholas Medcalf and Volk, {Hans Dieter} and Petra Reinke",
year = "2016",
month = "3",
day = "14",
doi = "10.1016/j.jcyt.2016.05.005",
language = "English (US)",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Putting a price tag on novel autologous cellular therapies

AU - Abou-El-Enein, Mohamed

AU - Bauer, Gerhard

AU - Medcalf, Nicholas

AU - Volk, Hans Dieter

AU - Reinke, Petra

PY - 2016/3/14

Y1 - 2016/3/14

N2 - Cell therapies, especially autologous therapies, pose significant challenges to researchers who wish to move from small, probably academic, methods of manufacture to full commercial scale. There is a dearth of reliable information about the costs of operation, and this makes it difficult to predict with confidence the investment needed to translate the innovations to the clinic, other than as small-scale, clinician-led prescriptions. Here, we provide an example of the results of a cost model that takes into account the fixed and variable costs of manufacture of one such therapy. We also highlight the different factors that influence the product final pricing strategy. Our findings illustrate the need for cooperative and collective action by the research community in pre-competitive research to generate the operational models that are much needed to increase confidence in process development for these advanced products.

AB - Cell therapies, especially autologous therapies, pose significant challenges to researchers who wish to move from small, probably academic, methods of manufacture to full commercial scale. There is a dearth of reliable information about the costs of operation, and this makes it difficult to predict with confidence the investment needed to translate the innovations to the clinic, other than as small-scale, clinician-led prescriptions. Here, we provide an example of the results of a cost model that takes into account the fixed and variable costs of manufacture of one such therapy. We also highlight the different factors that influence the product final pricing strategy. Our findings illustrate the need for cooperative and collective action by the research community in pre-competitive research to generate the operational models that are much needed to increase confidence in process development for these advanced products.

KW - Adoptive T-cell therapy

KW - Commercialization

KW - Cost of goods

KW - Good manufacturing practice

KW - Immunotherapy

KW - Market adoption

KW - Price

KW - Regulation

KW - Reimbursement

KW - Scale-up

UR - http://www.scopus.com/inward/record.url?scp=84974815570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974815570&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2016.05.005

DO - 10.1016/j.jcyt.2016.05.005

M3 - Article

C2 - 27288308

AN - SCOPUS:84974815570

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

ER -